Q4 2024 SeQuent Scientific Ltd Earnings Call Transcript
Key Points
- Sequent Scientific Ltd (BOM:512529) achieved its highest EBITDA in the last 12 quarters, with a pre-ESOP cost of INR411 million.
- The company reported an EBITDA margin pre-ESOP cost of 11.4%, slightly ahead of its guidance.
- European operations showed strong growth, with a 7.9% year-on-year increase in Q4.
- The India formulations business grew by 9% year-on-year in Q4, driven by new product launches.
- The API business saw a strong sequential growth of 39% in Q4, with a 2% year-on-year increase.
- Overall revenue declined by 1.5% year-on-year in Q4, mainly due to a higher base in the previous year and discontinued businesses.
- The macro environment remains volatile, with inflation and currency issues affecting some markets.
- Turkey's inflation remains elevated at over 60%, posing challenges despite government actions.
- The emerging markets business has been weak, with currency challenges in regions like the Middle East affecting performance.
- Net debt increased to INR3,789 million as of March 31, 2024, compared to INR3,654 million in March 2023.
Ladies and gentlemen, good day, and welcome to the SeQuent Scientific Limited Q4 and FY24 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
Very good morning, and thank you for joining us today for SeQuent Scientific's earnings conference call for the fourth quarter and full year ended financial year 2024. Today, we will have with us Rajaram, SeQuent's Managing Director; and Saurav, CFO, to share the highlights of the business and financials for the quarter.
I hope you've gone through our results release and the quarterly investor presentation, which have been uploaded on our website, as well as stock exchange website. The transcript of this call will be available in a week's time on the company's website. Please note that today's discussion may be forward-looking in nature and must be viewed in relation to the risks pertaining to our business. After
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
